Invivyd, Inc. (Nasdaq: IVVD) today announced a peer-reviewed publication by Invivyd that uses data from the recent CANOPY pivotal clinical trial of Invivyd’s monoclonal antibody pemivibart to predict ...
The Company additionally announced progress in advancing an additional indication for tivoxavir marboxil (TXM), a potential best in class CAP-dependent endonuclease inhibitor, as a once-monthly, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results